Clayton Natasha P, Yoshizawa Katsuhiko, Kissling Grace E, Burka Leo T, Chan Po-Chuen, Nyska Abraham
Laboratory of Experimental Pathology, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA.
Exp Toxicol Pathol. 2007 Jan;58(4):223-36. doi: 10.1016/j.etp.2006.08.002. Epub 2006 Oct 23.
Kava (Piper methysticum), used for relaxation and pain relief, has been one of the leading dietary supplements and several reports linking hepatic functional disturbances and liver failure to kava have resulted in a ban on sales in Europe and Canada and the issuance of warnings by the US FDA. The National Toxicology Program conducted 14-week rat studies to characterize the toxicology of kava exposure in Fischer 344 rats [National Toxicity Program. 90 day gavage toxicity studies of KAVA KAVA EXTRACT in Fischer rats and B6C3F1 mice. Research Triangle Park, NC; 2005a; National Toxicity Program. Testing status of agents at NTP (KAVA KAVA EXTRACT M990058). Research Triangle Park, NC; 2005b. (http://ntp.niehs.nih.gov/index.cfm?objectid=071516E-C6E1-7AAA-C90C751E23D14C1B)]. Groups of 10 male and 10 female rats were administered kava extract by gavage at 0, 0.125, 0.25, 0.5, 1.0, and 2.0 g/kg/day. Increased gamma-glutamyl-transpeptidase (GGT) activities were observed in the 2.0 g/kg males and 1.0 and 2.0 g/kg females, as well as increased serum cholesterol levels in males and females at 0.5 g/kg and higher. Increases in incidence and severity of hepatocellular hypertrophy (HP) were noted in males at 1.0 g/kg and females at 0.5 g/kg and higher, as well as increased liver weights. Immunohistochemical analyses of the expression of cytochrome-P450 (CYP) enzymes in liver of the control and 1.0- and 2.0-g/kg-treated groups indicated decreased expression of CYP2D1 (human CYP2D6 homolog) in 2.0 g/kg females and increased expression of CYP1A2, 2B1, and 3A1 in 1.0 and 2.0 g/kg groups of both sexes. The no observed adverse effect levels were decided as 0.25 g/kg in both genders, based on neurotoxic effects, increases in GGT, cholesterol, liver weight, and HP and decreases in body weight. Kava-induced hepatic functional changes in the F344 rat might be relevant to human clinical cases of hepatotoxicity following exposure.
卡瓦(胡椒科植物卡瓦胡椒)用于放松和缓解疼痛,一直是主要的膳食补充剂之一。有几份报告将肝功能紊乱和肝衰竭与卡瓦联系起来,这导致其在欧洲和加拿大被禁止销售,美国食品药品监督管理局(FDA)也发布了警告。美国国家毒理学计划进行了为期14周的大鼠研究,以确定费希尔344大鼠接触卡瓦的毒理学特征[美国国家毒理学计划。卡瓦提取物对费希尔大鼠和B6C3F1小鼠的90天灌胃毒性研究。北卡罗来纳州三角研究园;2005年a;美国国家毒理学计划。NTP处受试物的测试状态(卡瓦提取物M990058)。北卡罗来纳州三角研究园;2005年b。(http://ntp.niehs.nih.gov/index.cfm?objectid=071516E-C6E1-7AAA-C90C751E23D14C1B)]。将10只雄性和10只雌性大鼠分为一组,分别以0、0.125、0.25、0.5、1.0和2.0克/千克/天的剂量经口灌胃给予卡瓦提取物。在给予2.0克/千克剂量的雄性大鼠以及给予1.0和2.0克/千克剂量的雌性大鼠中,观察到γ-谷氨酰转肽酶(GGT)活性增加,并且在给予0.5克/千克及更高剂量的雄性和雌性大鼠中,血清胆固醇水平升高。在给予1.0克/千克剂量的雄性大鼠以及给予0.5克/千克及更高剂量的雌性大鼠中,肝细胞肥大(HP)的发生率和严重程度增加,肝脏重量也增加。对对照组以及给予1.0和2.0克/千克处理组大鼠肝脏中细胞色素P450(CYP)酶表达的免疫组织化学分析表明,在给予2.0克/千克剂量的雌性大鼠中,CYP2D1(人类CYP2D6同源物)表达降低,在给予1.0和2.0克/千克剂量的雄性和雌性大鼠组中,CYP1A2、2B1和3A1表达增加。基于神经毒性作用、GGT、胆固醇、肝脏重量和HP的增加以及体重的降低,确定两性的未观察到有害作用水平均为0.25克/千克。卡瓦在F344大鼠中引起的肝功能变化可能与人类接触后发生肝毒性的临床病例相关。